Results 51 to 60 of about 4,880,179 (312)

Assessing drug safety [PDF]

open access: yesBMJ, 2005
EDITOR—Eaton reports that more surveillance of drugs is needed to protect the public.1 All drugs are dangerous, some may also be useful. If drug efficacy is easy to show, drug safety (low risk) is essentially unprovable: absence of demonstration of risk is not demonstration of absence.
openaire   +2 more sources

Experience With Performing Rheocarna Therapy via the Single‐Needle Method for Treatment of Chronic Limb‐Threatening Ischemia

open access: yesTherapeutic Apheresis and Dialysis, EarlyView.
ABSTRACT Introduction This study investigated the safety and efficacy of single‐needle Rheocarna therapy for chronic limb‐threatening ischemia (CLTI) with wounds. Methods Six patients with CLTI involving ulcers unresponsive to revascularization underwent single‐needle Rheocarna treatment.
Yasutaka Yamauchi   +9 more
wiley   +1 more source

Reporting Patterns Indicative of Adverse Drug Interactions

open access: yes, 2011
Background: Adverse drug interaction surveillance in collections of Individual Case Safety Reports (ICSRs) remains underdeveloped. Most efforts to date have focused on disproportionality analysis, but the empirical support for its value is based on ...
Bate, Andrew,   +12 more
core   +1 more source

Comparative Evaluation of Hemodiafiltration, Hemoperfusion, and Standard Hemodialysis on Efficacy, Inflammatory Control, Dialysis Adequacy, and Safety in End‐Stage Renal Disease: A Prospective Observational Study

open access: yesTherapeutic Apheresis and Dialysis, EarlyView.
ABSTRACT Background Chronic micro‐inflammation in patients with end‐stage renal disease (ESRD) is a significant driver of cardiovascular complications and diminished quality of life. While standard hemodialysis (SHD) effectively manages small‐molecule clearance, its ability to remove medium‐to‐large uremic toxins—the primary catalysts of systemic ...
Hongwei Zuo   +5 more
wiley   +1 more source

Evaluation of the Peer Support Program (Student Drug Prevention) 1986-1987

open access: yes, 2019
The Peer Support program is a school based program funded by the National Campaign Against Drug Abuse (NCADA) as a drug prevention strategy. Prior to the existence of the NCADA the program was funded through the NSW Drug and Alcohol Authority.
Directorate of the Drug Offensive
core   +1 more source

Safety of Daprodustat for the Treatment of Chronic Kidney Disease Anemia: Final Analysis of a Multicenter Postmarketing Surveillance Study in Japan

open access: yesTherapeutic Apheresis and Dialysis, EarlyView.
ABSTRACT Introduction This final analysis of a multicenter, prospective postmarketing surveillance study evaluated the safety of daprodustat in patients with chronic kidney disease anemia in routine clinical practice in Japan. Methods Patients who initiated daprodustat between September 2020 and July 2022 were registered.
Tadao Akizawa   +7 more
wiley   +1 more source

Introduction to drug utilization research [PDF]

open access: yes, 2003
Prepared by the WHO Collaborating Centre for Drug Statistics Methodology, the WHO Collaborating Centre for Drug Utilization Research and Clinical Pharmacological Services, and the International Working Group for Drug Statistics Methodology48 p.Korean ...
WHO International Working Group for Drug Statistics Methodology   +2 more
core  

Investigation of safety and efficacy of febantel and fenbendazole in fish and exposure assessment

open access: yesApplied Biological Chemistry
Fish are susceptible to blood-sucking parasite infections, which cause severe anemia, dyspnea, and ultimately death. However, veterinary drugs available for fish to treat such infectious diseases are lacking; thus, livestock drugs have been repurposed as
Min Ji Kim   +3 more
doaj   +1 more source

A peripherally restricted P2Y12 receptor antagonist altered rat tumor incidences with no human relevance: Mode of action consistent with dopamine agonism

open access: yesToxicology Reports, 2014
Background: Ticagrelor is an orally available, direct acting and reversible P2Y12 receptor antagonist approved for treatment of acute coronary syndrome.
David A. Brott   +7 more
doaj   +1 more source

Organoids in pediatric cancer research

open access: yesFEBS Letters, EarlyView.
Organoid technology has revolutionized cancer research, yet its application in pediatric oncology remains limited. Recent advances have enabled the development of pediatric tumor organoids, offering new insights into disease biology, treatment response, and interactions with the tumor microenvironment.
Carla Ríos Arceo, Jarno Drost
wiley   +1 more source

Home - About - Disclaimer - Privacy